AVELUMAB MASTER PROTOCOL: AN OPEN-LABEL CONTINUATION STUDY FOR PARTICIPANTS CONTINUING FROM PFIZER-SPONSORED AVELUMAB CLINICAL STUDIES.
AVELUMAB MASTER PROTOCOL: AN OPEN-LABEL CONTINUATION STUDY FOR PARTICIPANTS CONTINUING FROM PFIZER-SPONSORED AVELUMAB CLINICAL STUDIES.
This Master Protocol for Avelumab Continuation Sub-Studies is to provide continued treatment access, safety follow-up, and when applicable, overall survival follow-up for eligible participants who continue to derive a benefit from study intervention in the Pfizer-sponsored Avelumab parent studies.
B9991046 is a master protocol that will consist of sub-studies from the following parent studies:
B9991001 - NCT02603432 B9991003 - NCT02684006 B9991004 - NCT02554812 B9991005 - NCT02584634 B9991009 - NCT02580058 B9991023 - NCT03317496 B9991025 - NCT03330405 B9991027 - NCT03472560 B9991032 - NCT03565991
Inclusion Criteria:
Exclusion Criteria:
Long Island City, New York 11101, United States
New York, New York 10021, United States
Philadelphia, Pennsylvania 19104, United States
Ancona, 60126, Italy
Chuo-ku, Tokyo 104-0045, Japan
Koto, Tokyo 135-8550, Japan
Warsaw, 02-781, Poland
Omsk, Omsk Oblast 644013, Russia
Ufa, 450054, Russia
Namdong-gu, Incheon-gwangyeoksi [incheon] 21565, South Korea